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Abstract
Background
Recently a large clinical trial showed that the use of 13-valent pneumococcal conjugate vac-
cine (PCV13) among immunocompetent individuals aged 65 years and over was safe and
efficacious. The aim of this study was to assess the cost-effectiveness of vaccinating immu-
nocompetent 65 year olds with PCV13 vaccine in England. England is a country with univer-
sal childhood pneumococcal conjugate vaccination programme in place (7-valent (PCV7)
since 2006 and PCV13 since 2010), as well as a 23-valent pneumococcal polysaccharide
(PPV23) vaccination programme targeting clinical risk-groups and those65 years.
Method
A static cohort cost-effectiveness model was developed to follow a cohort of 65 year olds
until death, which will be vaccinated in the autumn of 2016 with PCV13. Sensitivity analysis
was performed to test the robustness of the results.
Results
The childhood vaccination programme with PCV7 has induced herd protection among older
unvaccinated age groups, with a resultant low residual disease burden caused by PCV7
vaccine types. We show similar herd protection effects for the 6 additional serotypes
included in PCV13, and project a new low post-introduction equilibrium of vaccine-type dis-
ease in 2018/19. Applying these incidence projections for both invasive disease and
community-acquired pneumonia (CAP), and using recent measures of vaccine efficacy
against these endpoints for65 year olds, we estimate that vaccination of a cohort of immu-
nocompetent 65 year olds with PCV13 would directly prevent 26 cases of IPD, 69 cases of
CAP and 15 deaths. The associated cost-effectiveness ratio is £257,771 per QALY gained
(using list price of £49.10 per dose and £7.51 administration costs) and is therefore consid-
ered not cost-effective. To obtain a cost-effective programme the price per dose would need
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to be negative. The results were sensitive to disease incidence, waning vaccine protection
and case fatality rate; despite this, the overall conclusion was robust.
Conclusions
Vaccinating immunocompetent individuals aged65 years with PCV13 is efficacious. How-
ever the absolute incidence of vaccine-type disease will likely become very low due to wider
benefits of the childhood PCV13 vaccination programme, such that a specific PCV13 vacci-
nation programme targeting the immunocompetent elderly would not be cost-effective.
Background
Community acquired pneumonia (CAP) causes a high disease burden among the aging popu-
lation. The bacterium Streptococcus pneumoniae is the single most common bacterial cause of
CAP, with an estimated 5%-40% of cases caused by this pathogen [1–3]. Furthermore, S. pneu-
moniae causes invasive disease (IPD) associated with a high mortality depending on age and
risk-group [4]. For this reason many developed countries have introduced a pneumococcal
vaccination programme targeting those aged 65 years and over using the 23-valent polysaccha-
ride vaccine (PPV23) which covers 23 of the 90+ known pneumococcal serotypes. Unfortu-
nately, due to a relatively low efficacy and short duration of protection against IPD, and lack of
protection against pneumococcal-attributable CAP, PPV23 has had little overall impact on
pneumococcal disease in the 65+ age group. [5–7].
Recently the results of a large clinical trial [clinical trial registration number NCT00744263]
in the Netherlands showed that the 13-valent pneumococcal conjugate vaccine (PCV13) cur-
rently used in the childhood vaccination programme of many countries has an efficacy of
45.6% (95% CI 21.8%-62.5%) against vaccine-type CAP and 75% (95% CI 41.4%-90.8%)
against IPD among those aged 65 years and older [8].
In this study we investigate the cost-effectiveness of adding PCV13 to the current PPV23
vaccination schedule targeting those aged 65 years and over in England. To make a realistic
projection of the future incidence of vaccine-type CAP and IPD in this age group, the herd pro-
tection effects from the childhood pneumococcal vaccination programme, in which the
7-valent PCV (PCV7) has been recommended for all infants since September 2006 and PCV13
since 2010, were taken into account.
Methods
Programme
In this study we investigate the cost-effectiveness of offering PCV13 to all 65 year olds in
England. This would be an addition to the current PPV23 programme in which a dose of
PPV23 is offered to any 65 year old who has not previously received a dose at any time in the
past. To make a realistic projection of the future incidence of vaccine-type CAP and IPD in this
age group, the herd protection effects from the childhood pneumococcal vaccination pro-
gramme, in which the 7-valent PCV (PCV7) has been recommended for all infants since Sep-
tember 2006 and PCV13 since 2010, were taken into account. It is assumed that PCV13 will be
provided at the same time as seasonal influenza vaccine, but that PPV23 will need an additional
visit to the general practitioner (GP) eight weeks later. Therefore the new programme will
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require one extra GP visit compared to the current schedule. The first season of use was set to
be 2016/2017.
Study Population
The study population was set to be a cohort of people who reflect the targeted population of
the clinical trial. This cohort comprised immunocompetent individuals including those with
co-morbidities such as diabetes, asthma, splenectomy or heart, liver or lung disease. The clini-
cal trial excluded those living in nursing homes or long term care facilities but due to lack of
data on pneumococcal disease burden in these groups in England it was not possible to exclude
such individuals from analysis.
Incidence of IPD
The incidence of IPD by vaccine-type (PCV7 and PCV13 minus 7) was based on the serotype-
specific surveillance data collated by Public Health England for the epidemiological years July
to June from 2002/03 to 2013/2014. Details of these incidence estimates for England andWales
have been recently published by Waight et.al. [9]. We corrected for changes in surveillance sen-
sitivity over time by increasing the incidence of IPD before 2009/10 as previously described [9].
Incidence of CAP
Recently Rodrigo and colleagues [10] published a survey of community acquired pneumonia
in two large teaching hospitals in Nottingham (UK). Over a period of five years (September
2008 until September 2013) urine samples were collected from participants (aged16 years)
following admission with acute lower respiratory symptoms. Samples were tested with a vali-
dated multiplex immunoassay (detecting 14 serotypes/groups, including all PCV 13 types) and
the immunochromatographic assay kit BinaxNOW™ (Alere) which detects pneumococcal
polysaccharide. In addition, blood samples were cultured for S. pneumoniae and positives sero-
typed by slide agglutination. Annual incidences for vaccine types (PCV7 and PCV13 minus 7)
were estimated using the population data from the Office of National Statistics for the greater
Nottingham area. To our knowledge this is the largest longitudinal survey that documents the
impact of PCV vaccination on vaccine-type pneumococcal pneumonia in the UK, hence we
used the observations from this study in our projections (see also S1 Appendix).
Projecting Future Incidence
To estimate the future incidence for IPD and CAP caused by the PCV7 and PCV13 minus 7
vaccine types it was assumed that:
a. PCV7 types reached a new post-vaccination equilibrium in IPD in 2013/14.
b. The additional 6 types covered by PCV13 will experience a similar reduction in IPD as the
PCV7-types, with a similar post-vaccination steady state. (see S2 Appendix for evidence in
support of this assumption)
c. The incidence of PCV13-VT pneumococcal CAP will follow a similar downward trend as
IPD.
To implement part b the IPD incidence rate ratio for PCV7 types was calculated for the
period since introduction of PCV-7 (2006/07 until the most recent data) using the pre-PCV7
period 2002/03-2005/06 as baseline incidence. Subsequently this incidence rate ratio was used
to project the IPD incidence for 2014/2015 onwards for the PCV13 minus PCV7 types, using
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the pre-PCV13 incidence in the years 2007–2011 as baseline. To project the incidence of PCV7
and PCV13 minus 7 CAP as described in part c, the ratio between CAP and IPD was calculated
by ordinary least squares for the period 2008–2013, the years for which overlapping data was
available. Subsequently this ratio was used to predict the future incidence of CAP based on the
projected IPD incidence.
Vaccine Efficacy and Coverage
In the clinical trial population (per protocol analysis) the protection was 75% against
PCV13-type IPD and 45.6% against PCV13-type CAP [8]. For CAP there were also age-strati-
fied results: 52.4% (95% CI 24.1%-71.0%) protection among those aged under 75 and 46.4%
(95% CI -4.3%-73.6%) for those age75 and<85, and no efficacy among those age 85 years
and over (6 cases in vaccine arm vs 3 in the placebo arm) [8]. However, in a programmatic set-
ting the intention-to-treat analysis is more applicable, as the vaccinated cohort will include
those who develop immunocompromised conditions. Unfortunately no age specific estimates
were available using the intention-to-tread analysis, but as the overall estimate was lower
(37.7%) the non-age specific estimate of 45.6% was applied, being a compromise between the
younger age and the inclusion of those who will develop immunocompromised conditions.
The average duration of follow-up in the trial was almost 4 years, and in these four years there
was not an obvious decline in protection (although there was simultaneously a decline in the
force of infection of some PCV13 vaccine types due to the herd immunity impact of the 10–
valent PCV childhood vaccination programme introduced in the Netherlands in 2011 and
which covered the same serotypes as PCV13 apart from 3, 6A and 19A.) [8]. Given the limited
duration of follow up in the trial population we did not assume lifelong protection from
PCV13. To be conservative we used a waning scenario developed by the manufacturer Pfizer
which assumes a constant protection for the first 9 years after which it drops every 5 years until
there is a constant protection from 20 years onward (Cost-effectiveness analysis of adult vacci-
nation with the 13-valent Pneumococcal Conjugate Vaccine in the United Kingdom, unpub-
lished report provided to the authors by Pfizer). The protection against IPD was respectively
75% (year 1–9), 43% (year 10–14), 9% (year 15–19), and 5% (years 20+); for CAP this was
45%, 26%, 5% and 3%. The vaccine uptake was set to be 69%, in line with the uptake of the
PPV23 vaccine in those aged 65 years and over [11].
Mortality, Life Expectancy and Quality of Life
The loss in quality of life due to pneumococcal disease was similar to that applied in Rozen-
baum et al [12], a previous cost-effectiveness study on the use of PCV13 in high risk groups
including those aged65 years in the UK conducted before the clinical trial results became
available and which assumed in its base case no protection from PCV13 against vaccine-type
CAP. For IPD various sequelae from meningitis were included and adjusted for the fact that
one person can have multiple sequelae at the same time. The assumed rate for meningitis was
6% [12] and the assumed duration of sequelae was lifelong. The overall QALY loss due to IPD
was between 0.14 (aged 65) and 0.01 (aged 100) depending on age. The assumed QALY loss
due to CAP was set on 0.006 [12]. The case fatality rate (CFR) was assumed to be 30% and 10%
for IPD and CAP respectively. Both parameters are uncertain; the IPD CFR was based on a
study in which laboratory confirmed IPD data was linked to hospital records to ascertain
deaths during an IPD admission [4]; the CFR for CAP was set as a compromise, as various
sources report great differences in rates, from 1.8% in the CAPITA trial [8], 6.2% in the
Rodrigo study and over 20% based on computerised hospital discharge data for admissions
with a code for all cause pneumonia [13]. The effect of varying the CFR for IPD and CAP was
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investigated in a sensitivity analysis. The quality adjusted life expectancy was estimated using
the most recent mortality rates [14] and the background quality of life was as estimated by Pet-
rou [15]. A scenario analysis was performed using a longer life expectancy estimated for a
cohort of non-risk people (excluding all clinical risk groups recommended to receive PPV23
under the age of 65). Persons could not become older than 105, hence the maximum follow-up
for a 65 year old was 40 years.
Costs
The cost of hospitalisation due to IPD and CAP was based on Rozenbaum et al. [12] and
inflated to 2014 costs using the Hospital & Community Health Service Index [16]. The price
for IPD was between £4865 (age 65) and £4780 (age 100) and £715 for CAP. The current price
of PCV13 in the British National Formulary is £49.10 [17] and this price was used in the base
case. The administration costs due to the additional dose was set to be £7.51.
Economic Model
A static cohort model was used to estimate the future incidence, cost and disease burden for
specific ages. In the model cohorts were followed from their point of entry in the season of
2016/2017 until death. The incremental cost-effectiveness ratio was calculated from a health
care payer’s perspective and cost and QALYs were both discounted by 3.5% per annum.
To achieve an understanding of the relation between the cost-effectiveness ratio and vaccine
price we performed various sensitivity analyses to test the cost-effectiveness ratio with a vaccine
price of £49.10 and the price at which the vaccine becomes cost-effective using a threshold of
£20,000 as is recommended in the UK [18]. The robustness of the outcome was tested by vary-
ing the assumptions on costs, QALY loss, case fatality rate, incidence, waning of vaccine pro-
tection, age at first dose, life expectancy, timing of introduction.
The decision taken by the UK Joint Committee on Vaccination Immunisation on the use of
PCV13 in those aged 65 years and over was split into two steps; first a decision on the use of
PCV13 in the general (immunocompetent) population and secondly a decision on the use of
the vaccine in clinical risk-groups. In the presented base-case analysis the immunocompetent
population includes people in clinical risk-groups; therefore we have added a scenario which
focuses on the cost-effectiveness among those who have no underlying co-morbidity. The inci-
dence presented in Waight et al. [9] is for all individuals irrespective of co-morbidities. To
adjust this population incidence to reflect those who are not in a clinical-risk group we
assumed that 55% of the population aged 65 years and over is not in a high risk group [4] and
that the odds ratio of hospitalisation if in a risk versus a non-risk group is 2.7 [4]. This implies
that the incidence would be 55% lower in the “non-risk” group. (See S3 Appendix)
Results
The observed (and projected) incidence of invasive disease due to PCV7 serotypes has become
very low, with an incidence below or around 1 per 100,000 (depending on age), with the highest
incidence among those age 85 years and over (see Fig 1). The incidence rate ratio compared to
the pre-vaccine period is around 3% (Table 1). The projected incidence for PCV13 minus
PCV7 types is expected to reach its steady state in the season 2018/19 after when it is assumed
that the incidence will remain low (Table 2, Fig 2). Due to the higher circulation of PCV7 types
before introduction of the vaccine it is projected that in the long term more disease will be
caused by PCV7 types than the additional 6 serotypes in PCV13. The incidence rate ratio for
both the PCV7 and PCV13 minus PCV7 is similar using the first three post-vaccination years
(see Fig 3). The incidence of CAP due to PCV7 and PCV13 minus 7 serotypes was projected to
Cost-Effectiveness of Vaccinating65 Year Olds with PCV13
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Fig 1. Observed and projected incidence for invasive pneumococcal disease caused by the PCV7 vaccine types per 100.000 persons for the
epidemiological years 2002/03 until 2019/20 in three age groups 65–74 (black), 75–84 (light grey) and 85 and over (dark grey line). Future
projections, see text, are shown by a dotted line.
doi:10.1371/journal.pone.0149540.g001
Table 1. Estimated IPD to CAP incidence rate ratio over the period 2008/09 to 2012/2013.
Age group PCV7 PCV13 minus PCV7
65–74 5.9 3.0
75–84 4.4 2.6
85+ 10.1 4.0
doi:10.1371/journal.pone.0149540.t001
Table 2. Projected future incidence of Invasive pneumococcal disease (IPD) and Community
Acquired Pneumonia (CAP) caused by the PCV13 vaccine types per 100,000. In 2018/2019 a new
steady state was assumed to be reached and the same incidence was continued after.
2015/2016 2016/2017 2017/2018 2018/2019
Projected IPD caused by PCV13-types
65–74 1.10 0.88 0.71 0.49
75–84 2.04 1.44 1.15 1.10
85+ 3.76 2.80 1.99 1.62
Projected CAP caused by PCV13-types
65–74 4.17 3.50 2.95 2.31
75–84 6.55 4.99 4.24 4.13
85+ 21.45 17.59 14.40 12.93
doi:10.1371/journal.pone.0149540.t002
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Fig 2. Observed and projected incidence for invasive pneumococcal disease caused by the PCV13minus PCV7 vaccine types per 100.000
persons for the epidemiological years 2002/03 until 2019/20 in three age groups 65–74 (black line), 75–84 (light grey line) and 85 and over (dark
grey line). Future projections, see text, are shown by a dotted line. The incidence in 2018/19 and 2019/20 will continue into the future.
doi:10.1371/journal.pone.0149540.g002
Fig 3. Observed incidence rate ratios for PCV7 vaccine types and PCV13minus PCV7 serotypes in the three years after vaccination compared to
the four years before vaccination (2002/03 to 2005/06 for PCV7 and 2007/08 to 2010/2011 for PCV13minus PCV7). The dark shaded bars represent
PCV7 and the light shaded bars PCV13 minus PCV7 types.
doi:10.1371/journal.pone.0149540.g003
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reduce to low incidences in line with the reductions in IPD (Table 2, Figs 4 and 5 respectively).
Overall, an expanding herd immunity effect induced by the childhood vaccination programme
is observed, resulting in low incidences for vaccine type disease (both IPD and CAP) in those
age 65 and over.
Using the projected incidences by age, by year, and the assumptions in the cost-effectiveness
model (Table 3) it is possible to project the disease burden in a cohort of 442,435 65 year olds
until death from 2016 until 2056 with a vaccine uptake of 69%. Using the projection it is esti-
mated that there will be 82 cases of vaccine type IPD and 426 cases of vaccine type CAP and a
total of 67 deaths in a cohort of 442,435 65 year olds, linked to a total cost of just over £0.7 mil-
lion (£0.4 million discounted) and 367 QALYs lost (257 discounted). With a vaccination pro-
gramme this will be 56 cases of IPD and a remaining 357 cases of CAP and a total of 52 deaths,
and £0.5 million costs (£0.3 million discounted) and 257 QALYs (160 discounted).
Assuming a vaccine price of £49.10 per dose the estimated cost per gained QALY is
£257,771 and the maximum price to achieve an ICER of £20,000 lies below zero (-£2.83) per
dose (on top of the administration costs) (Table 4) The outcome is not very sensitive to the
assumed costs and QALY loss for acute disease; however, it is very sensitive to the CFR, waning
vaccine-induced protection, as well as the projected incidence of IPD. The optimal age of vacci-
nation is 75 years due to the waning protection and the increase in incidence with age. Even
assuming that incidence of PCV13-type IPD and CAP reduce no further after 2015/16, the cost
per QALY averted is £145,146, and the maximum price to achieve an ICER of £20,000 is £0.79
(see Table 5).
Fig 4. Observed and projected incidence for community acquired pneumonia caused by PCV7 vaccine types per 100.000 for the epidemiological
years 2008/09 until 2019/20 in three age groups 65–74 (black line), 75–84 (light grey line) and 85 and over (dark grey line).Model projections, see text,
are shown by a dotted line. The incidence in 2018/19 and 2019/20 will continue into the future.
doi:10.1371/journal.pone.0149540.g004
Cost-Effectiveness of Vaccinating65 Year Olds with PCV13
PLOSONE | DOI:10.1371/journal.pone.0149540 February 25, 2016 8 / 14
Discussion
In this analysis we investigated a scenario in which there is a residual burden of vaccine type
IPD and CAP despite the herd immunity effects of the paediatric PCV programme. In the base
case, and under the most conservative assumption that there will be no further reduction in
PCV13 type IPD and CAP after 2015/16, vaccination of the immunocompetent elderly is very
Fig 5. Observed and projected incidence for community acquired pneumonia caused by PCV13minus PCV7 vaccine types per 100.000 for the
epidemiological years 2008/09 until 2019/20 in three age groups 65–74 (dark line), 75–84 (light grey line) and 85 and over (dark grey line).Model
projections, see text, are shown by a dotted line. The incidence in 2018/19 and 2019/20 will continue into the future.
doi:10.1371/journal.pone.0149540.g005
Table 3. Assumptions in the base case cost effectiveness analysis.
Parameter IPD CAP
Vaccine efﬁcacy
Year 1–9 75% 45%
Year 10–14 43% 26%
Year 15–19 9% 5%
Years 20+ 5% 3%
Costs
Hospitalisation (incl. sequelae) £4858-£4780 (age dependent) £715
Case fatality rate
CAP 30% 10%
QALY loss
CAP 0.13–0.01 (age dependent) 0.006
Discounting Costs QALYs
Costs 3.5% 3.5%
doi:10.1371/journal.pone.0149540.t003
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unlikely to be cost-effective under the current list-price (£49.10). Due to the additional GP visit
and the related administration costs when both PPV23 and PCV13 are used the budget which
remains available to purchase the vaccine translates into a cost of below £0 per dose in the base
case scenario. Even if the administration cost was zero, the price per dose would need to be
below £5.
There are several uncertainties in our assessment. The first is the applied future incidence
for both IPD and pneumococcal CAP. In our analysis we investigated a base case where the
future was based on the observed reduced rate of IPD caused by PCV7 serotypes in those aged
65 years and over as the result of the PCV7 and PCV13 vaccination programmes for infants.
Table 4. Results of the cost effectiveness analysis according to incremental cost effectiveness ratio (ICER) andmaximum price per dose; base
case and sensitivity analysis.
ICER using £49.10 per dose and £7.51
administration costs)
Max price per dose (after subtracting £7.51 administration costs)
using a threshold of £20,000 per QALY
Base case £257,771 -£2.83
Sensitivity analysis
Double hospital costs £256,431 -£2.53
0.05 QALY loss both IPD CAP £249,357 -£2.68
15%/5% CFR IPD/CAP £512,829 -£5.00
30%/15% CFR IPD/CAP £209,423 -£1.82
Age 70 £268,787 -£2.94
Age 75 £262,316 -£2.74
Age 80 £322,910 -£3.53
No waning £169,638 -£0.29
No back ground QALY loss £191,863 -£1.33
Extra long life expectancy £228,661 -£2.27
Double the CAP incidence
measured by Rodrigo etal.
£175,664 -£0.71
Long term equilibrium (2018) £287,060 -£3.30
Incidence 55%, to reﬂect no risk £469,861 -£4.93
doi:10.1371/journal.pone.0149540.t004
Table 5. Incidence of vaccine-type IPD and CAP as applied by year in the model, and the cost-effectiveness andmaximum price per dose (thresh-
old of £20,000) for the corresponding incidence in case this would be the long-term incidence.
2013/2014 2014/2015 2015/2016 2016/2017 2017/2018 2018/19
Vaccine type IPD
65–74 2.7 1.7 1.1 0.9 0.7 0.5
75–84 5.2 2.6 2.0 1.4 1.1 1.1
85+ 8.1 4.6 3.8 2.8 2.0 1.6
Vaccine type CAP
65–74 9.1 6.1 4.2 3.5 3.0 2.3
75–84 14.7 8.0 6.5 5.0 4.2 4.1
85+ 38.5 24.7 21.5 17.6 14.4 12.9
Base case scenario
ICER £60,664 £98,767 £145,146 £181,667 £222,378 £287,060
Price/dose £12.10 £4.63 £0.79 -£0.87 -£2.08 -£3.30
Scenario restricted to non-risk group population
ICER £98,896 £160,491 £234,824 £293,834 £359,560 £462,838
Price/dose £4.55 -£0.05 -£2.39 -£3.42 -£4.17 -£4.91
doi:10.1371/journal.pone.0149540.t005
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This rate reduction was applied to the remaining serotypes covered by PCV13 in invasive dis-
ease for future years, and then the incidence of pneumococcal CAP was extrapolated from the
trend in IPD. We assumed for the base case that the 97% reduction in PCV7 type IPD observed
in both 2012/13 and 2013/14 in those aged 65 years and over represents the level at which
PCV7 type IPD will remain in the future and that the reduction in PCV13 minus 7 type IPD
will follow a similar trajectory after the change to PCV13 but with a delay of a year relative to
the PCV7 herd effect due to the lack of a catch-up programme. The observed similarities in
rate reduction between PCV7 and PCV13 for the three years for which there is similar data
supported the use of the decline among PCV7 types to project the decline among PCV13 types.
The extrapolation of disease trends in IPD towards pneumococcal CAP is justified for two rea-
sons; firstly a similar proportionate reduction in both IPD [9] and pneumococcal CAP [10]
was shown in the post-vaccination period in England (S2 Appendix) suggesting a herd protec-
tion effect by the childhood vaccination programme. Secondly, this herd protection effect can
only originate from a reduced transmission of the vaccine-types in the population. This accords
with the lower carriage rates for vaccine-type serotypes among non-vaccinated cohorts shown
in England for both PCV7 [19] and PCV13-7 types [20]. As both IPD and pneumococcal CAP
incidence depend on the transmission of vaccine-types, similar trends are expected in both dis-
ease presentations. A second uncertainty is the overall health benefit of the vaccination pro-
gramme on prevented mortality. In this there are three factors: these are 1) the risk of death
given CAP or IPD, 2) the future life expectancy of a person if they would not have died and 3)
the quality of life this person would have enjoyed for the remaining life time. The CFR rate for
IPD was based on a 30-day mortality in hospital among laboratory confirmed cases, without
an assessment of causality, therefore this is likely to be an overestimation. The CFR due to CAP
is not clear. Among the 185 identified cases of pneumococcal CAP in the CAPiTA trial there
were only 7 deaths, corresponding to a mortality rate of 3.8% (and only 2 out of 112 VT
CAP = 1.8%). In the pneumonia study from Nottingham used for the incidence of vaccine type
CAP in this study the mortality was 8.2% in the total cohort (all cause CAP) and 6.3% among
those with pneumococcal CAP. A recent meta-analysis of mortality in 23 studies of the out-
come of CAP showed that the overall CFR was 4.3% in randomised controlled trials and 5.5%
in observational studies; the total number of subjects included in the meta-analysis was
137,574, and the mean ages of participants ranged from 59 to 79 years across the studies [19].
This shows that the 10% CFR for CAP used in the base case is likely to be a high estimate. The
life expectancy used is the life expectancy observed in the overall population, but in the sensi-
tivity analysis it was shown that using a longer life expectancy did not influence the outcome
much. In cross-sectional surveys of the quality of life in the general population older people
score lower, as was included in our analysis. However, even if this background decrement in
quality of life with age is ignored, a PCV13 programme for 65 year olds would not be cost effec-
tive. A third uncertainty is the duration of protection. This is a major uncertainty in the overall
cost-effectiveness for this vaccine, and without additional data will remain speculative. How-
ever, the base case scenario with no decrement for the first 10 years is likely to be conservative.
It is important to match the study population with the population in the clinical trial from
which the vaccine estimates are derived. Although the CAPiTA trial excluded severely immu-
nocompromised people it did include most people with co-morbidities (only 0.3% of recruited
people were excluded based on clinical criteria). Therefore we decided to use the IPD and CAP
incidence in the general population but performed a sensitivity analysis in which the incidence
was lowered and the life expectancy was increased. This only reduced the cost-effectiveness
and decreased the cost effective price for the vaccine. The costs and QALY loss were based on a
previous study but remain uncertain parameters. In the sensitivity analysis however we show
that these assumptions did not influence the overall outcome much.
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A recent review of cost-effectiveness studies addressing the same question [21] found that 9
out of the 10 available analysis considered vaccination of those 65 and older with PCV13 cost-
effective. However, most of these studies were performed before the publication of the clinical
trial results, and other assumptions, such as the assumed herd immunity effect of a childhood
immunisation programme on the vaccine-type disease burden in other age groups, were not
always informed by robust evidence. The one study included in the review with similar findings
was our previous study in which showed that vaccinating clinical risk-groups in England with
PCV was not cost-effective [12]. Furthermore, a more recent cost-effectiveness study in the
Netherlands [22] found that it is not cost-effective to vaccinate immunocompetent elderly aged
between 65 and 74 years with PVC13. Interestingly the latter was under a scenario with a
10-valent childhood vaccination programme in place after several years of PCV7, in the study
it was assumed that the PCV10 programme would have no indirect effects on the 3 additional
serotypes included in PCV10 and no cross-protection against the 3 additional serotypes
included in PCV13. They investigated however a medium-risk group of persons who are
immunocompetent but have underlying conditions, as it is programmatically difficult to iden-
tify these people this risk-group was not included in this analysis.
The finding of this study supported the decision of the Joint Committee for Vaccination
and Immunisation (JCVI) [to be cited] that PCV13 will not be universally recommended for
those aged 65 years and over in England. This in contrast to the United States where PCV13 is
recommended among adults aged 65 years [23]. The JCVI decision acknowledges the
extended benefit of the childhood PCV vaccination programme outside the targeted age groups
as revealed by the serotype specific IPD surveillance and additional pneumococcal carriage and
CAP studies.
Future research should focus on continued monitoring of the circulating vaccine-types.
Should the projected declines in IPD and CAP incidence for the 6 additional serotypes in
PCV13 are markedly different from the declines in disease due to the 7 serotypes in PCV7,
revision of the above conclusions would be warranted.
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